Synthroid vs Tirosint: Cost, Access, and Clinical Differences Compared

Why Two Formulations of the Same Drug Exist

Levothyroxine is the most prescribed medication in the United States, with over 100 million prescriptions dispensed annually according to IQVIA data reported by the FDA. The standard compressed tablet (branded as Synthroid, Levoxyl, or Unithroid) has served as standard-of-care thyroid replacement since the 1960s. Tirosint, approved by the FDA in 2006, introduced a gel capsule formulation containing levothyroxine dissolved in gelatin with only glycerin and water as excipients.

The rationale behind Tirosint's development centers on a well-documented clinical problem. Tablet levothyroxine relies on disintegration and dissolution in the stomach before absorption in the jejunum and upper ileum. That process is pH-dependent and sensitive to interference from food, fiber, calcium, iron, proton pump inhibitors (PPIs), and conditions that alter gut transit or mucosal integrity [1]. The 2014 American Thyroid Association (ATA) guidelines acknowledge that malabsorption, concurrent medications, and GI conditions can destabilize levothyroxine tablet absorption, sometimes requiring dose escalation of 25% to 50% [1].

Tirosint bypasses the dissolution step entirely. The drug is already in solution inside the capsule shell.

Head-to-Head Absorption Data

No large randomized controlled trial has directly compared Synthroid to Tirosint in a general hypothyroid population. The comparison data that exists focuses on patients with known absorption challenges.

Vita et al. published a prospective crossover study in Endocrine (2014, N=34) examining patients with impaired levothyroxine tablet absorption due to concurrent PPI use, GI disease, or post-bariatric surgery anatomy [2]. After switching from tablet levothyroxine to Tirosint at the same microgram dose, patients achieved significantly lower TSH values (mean TSH decreased from 4.2 to 1.6 mIU/L, P<0.001) without dose adjustment [2]. Free T4 levels rose correspondingly.

A separate pharmacokinetic study by Brancato et al. (Therapeutic Advances in Endocrinology and Metabolism, 2015) confirmed that the liquid gel cap formulation showed less TSH variability when co-administered with a PPI compared to tablet levothyroxine. For patients on omeprazole 40 mg daily, tablet levothyroxine required a mean 37% dose increase to maintain target TSH, while the gel cap formulation maintained stable levels at the original dose.

These findings do not mean Tirosint is "better" across all patients. For the roughly 80% to 85% of hypothyroid patients who achieve stable TSH on standard tablets taken correctly, the gel cap formulation offers no measurable clinical advantage. The ATA guidelines recommend tablet levothyroxine as first-line therapy and suggest alternative formulations only when absorption is documented as unreliable [1].

Cost Breakdown: What You Will Actually Pay

Price is the single largest practical difference between these two drugs. The gap is substantial.

Synthroid (brand tablet, 100 mcg, 30-day supply):

• Average retail cash price: $45 to $75 (GoodRx range, May 2026)
• With commercial insurance (tier 1-2): $5 to $25 copay
• Generic levothyroxine tablet: $4 to $15 cash price at most pharmacies

Tirosint (brand gel cap, 100 mcg, 30-day supply):

• Average retail cash price: $225 to $375
• With commercial insurance (tier 3, if covered): $50 to $100+ copay
• Generic levothyroxine gel cap (Amneal, limited availability): $100 to $180

Over a 12-month period, the annual cost difference between generic levothyroxine tablets (~$60/year) and brand Tirosint (~$3,000/year) is roughly 50-fold. Even comparing brand-to-brand (Synthroid vs Tirosint), the annual gap exceeds $2,000 for most patients paying out of pocket.

The FDA's Orange Book lists multiple AB-rated generic equivalents for Synthroid tablets, which drives competitive pricing. Tirosint's generic competition remains limited, with Amneal Pharmaceuticals holding the only approved gel cap alternative as of early 2026.

Insurance Coverage and Formulary Placement

Formulary position determines real-world access more than retail price. Here the gap widens.

Synthroid and its generic equivalents sit on tier 1 or tier 2 of virtually every commercial, Medicare Part D, and Medicaid formulary in the United States. No prior authorization is required. Pharmacy benefit managers (PBMs) frequently mandate generic substitution, meaning a Synthroid prescription may be dispensed as generic levothyroxine unless the prescriber writes "dispense as written."

Tirosint occupies a more complicated position. According to formulary data compiled by Medicare.gov's Plan Finder, Tirosint requires prior authorization on approximately 60% to 70% of Medicare Part D plans and sits at tier 3 (preferred brand) or tier 4 (non-preferred) on most commercial plans. Some PBMs exclude it entirely and require a documented trial-and-failure of tablet levothyroxine before approving coverage.

To obtain prior authorization for Tirosint, most insurers require documentation of at least one of the following:

• Persistent TSH instability despite confirmed adherence to tablet levothyroxine
• Diagnosed malabsorptive condition (celiac disease, inflammatory bowel disease, short bowel syndrome, post-bariatric anatomy)
• Documented intolerance or allergy to tablet excipients (lactose, dyes, acacia)
• Concurrent medication creating verified absorption interference (PPIs, calcium, iron) that cannot be separated by timing

Dr. Elizabeth Pearce, former president of the American Thyroid Association, has noted that "levothyroxine tablet formulations are effective for the vast majority of hypothyroid patients, but clinicians should recognize that a subset of patients with absorption barriers may benefit from reformulation" [1].

Excipient Differences and Allergy Considerations

Synthroid tablets contain acacia, confectioner's sugar, lactose monohydrate, magnesium stearate, povidone, and talc, plus dye-specific colorants (FD&C Blue No. 1, Red No. 40, Yellow No. 6, among others depending on dose strength). For patients with lactose intolerance, dye sensitivity, or celiac disease, these excipients can cause GI symptoms or, in rare cases, measurably impair absorption.

Tirosint's formulation is strikingly minimal. Each gel cap contains only levothyroxine sodium, gelatin, glycerin, and water. No lactose. No dyes. No gluten. No sugar.

This distinction matters clinically for a specific population. A 2007 study by Virili et al. published in the Journal of Clinical Endocrinology & Metabolism demonstrated that celiac patients on a gluten-free diet still showed impaired tablet levothyroxine absorption compared to controls, and that this normalized with liquid/gel cap formulations [3]. For patients with confirmed celiac disease or documented excipient allergies, Tirosint represents a medically appropriate, not merely a convenient, alternative.

When Synthroid (Tablet Levothyroxine) Is the Right Choice

Standard tablet levothyroxine remains the correct first-line choice for most hypothyroid patients. The ATA's 2014 clinical practice guidelines recommend levothyroxine monotherapy as the standard of care, citing decades of outcome data and well-characterized pharmacokinetics [1].

Tablet levothyroxine is appropriate when the patient has no documented malabsorptive condition, can take the medication on an empty stomach 30 to 60 minutes before food, does not require concurrent PPIs or medications known to impair absorption, and achieves stable TSH on standard dosing. This describes the majority of the 15 to 20 million Americans treated for hypothyroidism.

Generic levothyroxine tablets carry AB-rated bioequivalence to Synthroid per the FDA, meaning the agency considers them therapeutically interchangeable. The one caveat: the ATA recommends that patients remain on the same manufacturer's product once stable, because small differences in bioavailability between manufacturers can shift TSH in sensitive individuals [1]. Switching generics at the pharmacy without notification remains a common cause of unexplained TSH fluctuations.

Dr. Bryan Haugen, past president of the ATA, has stated: "For patients stable on a given levothyroxine preparation, we recommend maintaining the same product. The issue is not brand vs generic but rather consistency of the preparation used" [1].

When Tirosint Makes Clinical Sense

Tirosint's higher cost is justifiable in specific, well-defined clinical scenarios supported by evidence.

Post-bariatric surgery patients. Roux-en-Y gastric bypass and biliopancreatic diversion alter the anatomy of the proximal small intestine, where most levothyroxine absorption occurs. The Vita et al. study demonstrated that these patients frequently require 25% to 50% dose increases on tablet levothyroxine but achieve target TSH at baseline doses when switched to Tirosint [2].

Concurrent PPI therapy. PPIs raise gastric pH, impairing tablet dissolution. Patients on long-term omeprazole, esomeprazole, or pantoprazole who cannot separate dosing by 4+ hours from levothyroxine are candidates for gel cap reformulation. The Brancato et al. data showed that gel cap levothyroxine maintained stable absorption even with simultaneous PPI administration.

Celiac disease or inflammatory bowel disease. Mucosal damage in the proximal small intestine directly impairs levothyroxine tablet absorption. Even well-controlled celiac patients on strict gluten-free diets may show suboptimal absorption of tablet formulations [3].

Documented excipient allergy. Patients with confirmed allergy to lactose, acacia, or FD&C dyes present in standard tablets may require the excipient-minimal gel cap.

Persistent TSH instability. Some patients demonstrate erratic TSH values (swinging from suppressed to elevated over months) despite confirmed adherence and consistent tablet brand. After ruling out adherence issues and medication interactions, switching to the gel cap formulation can reduce variability.

How to Switch Between Formulations

Switching from Synthroid to Tirosint (or vice versa) is done at a 1:1 microgram ratio. A patient on Synthroid 112 mcg switches to Tirosint 112 mcg. Both drugs contain the same active molecule at the same labeled strength.

The critical step is follow-up. The ATA recommends checking TSH 6 to 8 weeks after any formulation change to confirm stable levels [1]. Because Tirosint may be absorbed more efficiently than tablet levothyroxine in certain patients, some individuals will need a dose reduction after switching to avoid iatrogenic hyperthyroidism. Monitoring free T4 and TSH together provides the most complete picture.

Switching in the opposite direction (Tirosint to Synthroid) requires the same monitoring. Patients who were on Tirosint specifically because of absorption issues may see TSH rise after switching to tablets, requiring dose adjustment upward.

Availability and Pharmacy Access

Synthroid and generic levothyroxine tablets are stocked at essentially every pharmacy in the United States, including mail-order pharmacies, military pharmacies (TRICARE), and VA facilities. No distribution restrictions exist.

Tirosint availability is more variable. Most chain pharmacies (CVS, Walgreens, Rite Aid) can order it within 1 to 2 business days if not in stock. Specialty pharmacies and mail-order services typically maintain inventory. The Tirosint Direct program offered by the manufacturer provides home delivery with potential copay savings for commercially insured patients.

Patients filling Tirosint prescriptions should confirm their specific dosage strength is available before leaving the prescriber's office. Tirosint comes in 13 dosage strengths (13, 25, 37.5, 44, 50, 62.5, 75, 88, 100, 112, 125, 137, and 150 mcg), and lower-volume strengths may not be routinely stocked.

Patient Assistance and Copay Programs

Both manufacturers operate patient assistance programs for qualifying individuals.

AbbVie (Synthroid) offers a copay card reducing out-of-pocket costs to as low as $25 per month for commercially insured patients. Uninsured patients may qualify for free medication through AbbVie's patient assistance program with income verification.

IBSA/Akrimax (Tirosint) runs the Tirosint Direct program, which bundles home delivery with copay assistance. Commercially insured patients may pay as little as $35 per month. For uninsured or underinsured patients, the manufacturer's patient assistance program can provide Tirosint at no cost, subject to income eligibility (typically at or below 300% of the federal poverty level).

These programs change annually. Patients should verify current terms directly with the manufacturer or through resources like NeedyMeds or the pharmacy benefits coordinator at their clinic.

For Medicare Part D enrollees, manufacturer copay cards generally cannot be applied. These patients face full tier-3 or tier-4 copays unless their plan covers Tirosint at a lower tier or they qualify for Medicare Extra Help (Low Income Subsidy).

The Bottom Line on Value

The clinical question is not whether Tirosint is a "better" drug. It contains the same molecule. The question is whether a given patient's physiology requires the absorption advantages of a pre-dissolved gel cap formulation, and whether those advantages justify a roughly 5x to 50x price premium depending on insurance status.

For patients with documented malabsorption, concurrent PPI use that cannot be managed by dose timing, celiac disease, or excipient allergies, the answer is often yes. For patients stable on tablet levothyroxine with consistent TSH in the target range, switching to Tirosint adds cost without measurable clinical benefit.

Prescribers considering Tirosint should document the clinical rationale clearly in the medical record, both because prior authorization will require it and because the patient deserves to understand why one formulation is recommended over another. TSH should be rechecked at 6 weeks post-switch, with dose titration guided by the 0.5 to 2.5 mIU/L reference range endorsed by the ATA for most non-pregnant adults [1].